|
1
|
Cunningham I, Gee TS, Reich LM, Kempin SJ,
Naval AN and Clarkson BD: Acute promyelocytic leukemia: treatment
results during a decade at Memorial Hospital. Blood. 73:1116–1122.
1989.PubMed/NCBI
|
|
2
|
Ribeiro RC and Rego E: Management of APL
in developing countries: epidemiology, challenges and opportunities
for international collaboration. Hematology Am Soc Hematol Educ
Program. 162–168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sanz MA, Jarque I, Martin G, et al: Acute
promyelocytic leukemia. Therapy results and prognostic factors.
Cancer. 61:7–13. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang ZY and Chen Z: Acute promyelocytic
leukemia: from highly fatal to highly curable. Blood.
111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Niu C, Yan H, Yu T, et al: Studies on
treatment of acute promyelocytic leukemia with arsenic trioxide:
remission induction, follow-up, and molecular monitoring in 11
newly diagnosed and 47 relapsed acute promyelocytic leukemia
patients. Blood. 94:3315–3324. 1999.
|
|
6
|
Hu J, Liu YF, Wu CF, et al: Long-term
efficacy and safety of all-trans retinoic acid/arsenic
trioxide-based therapy in newly diagnosed acute promyelocytic
leukemia. Proc Natl Acad Sci USA. 106:3342–3347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu J, Lu Y, Wu Q, Goyer RA and Waalkes
MP: Mineral arsenicals in traditional medicines: orpiment, realgar,
and arsenolite. J Pharmacol Exp Ther. 326:363–368. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu DP, Qiu JY, Jiang B, et al:
Tetra-arsenic tetra-sulfide for the treatment of acute
promyelocytic leukemia: a pilot report. Blood. 99:3136–3143. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mao JH, Sun XY, Liu JX, et al: As4S4
targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL
in chronic myelogenous leukemia. Proc Natl Acad Sci USA.
107:21683–21688. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu J, Liang SX, Lu YF, Miao JW, Wu Q and
Shi JS: Realgar and realgar-containing Liu-Shen-Wan are less
acutely toxic than arsenite and arsenate. J Ethnopharmacol.
134:26–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen GQ, Shi XG, Tang W, et al: Use of
arsenic trioxide (As2O3) in the treatment of acute promyelocytic
leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL
cells. Blood. 89:3345–3353. 1997.PubMed/NCBI
|
|
12
|
Chen Z, Zhao WL, Shen ZX, et al: Arsenic
trioxide and acute promyelocytic leukemia: clinical and biological.
Curr Top Microbiol Immunol. 313:129–144. 2007.PubMed/NCBI
|
|
13
|
Chen GQ, Zhu J, Shi XG, et al: In vitro
studies on cellular and molecular mechanisms of arsenic trioxide
(As2O3) in the treatment of acute promyelocytic leukemia: As2O3
induces NB4 cell apoptosis with downregulation of Bcl-2 expression
and modulation of PML-RAR alpha/PML proteins. Blood. 88:1052–1061.
1996.
|
|
14
|
Cai X, Shen YL, Zhu Q, et al: Arsenic
trioxide-induced apoptosis and differentiation are associated
respectively with mitochondrial transmembrane potential collapse
and retinoic acid signaling pathways in acute promyelocytic
leukemia. Leukemia. 14:262–270. 2000. View Article : Google Scholar
|
|
15
|
Brill S, Li S, Lyman CW, et al: The Ras
GTPase-activating-protein-related human protein IQGAP2 harbors a
potential actin binding domain and interacts with calmodulin and
Rho family GTPases. Mol Cell Biol. 16:4869–4878. 1996.
|
|
16
|
Davison K, Mann KK and Miller WH Jr:
Arsenic trioxide: mechanisms of action. Semin Hematol. 397:3–7.
2002. View Article : Google Scholar
|
|
17
|
Ten Dijke P, Ichijo H, Franzen P, et al:
Activin receptor-like kinases: a novel subclass of cell-surface
receptors with predicted serine/threonine kinase activity.
Oncogene. 8:2879–2887. 1993.PubMed/NCBI
|
|
18
|
Qi J, He P, Chen W, Wang H, Wang X and
Zhang M: Comparative proteome study of apoptosis induced by As4S4
in retinoid acid resistant human acute promyelocytic leukemia
NB4-R1 cells. Leuk Res. 34:1506–1516. 2010. View Article : Google Scholar
|
|
19
|
Wu JZ and Ho PC: Evaluation of the in
vitro activity and in vivo bioavailability of realgar nanoparticles
prepared by cryo-grinding. Eur J Pharm Sci. 29:35–44. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xi RG, Huang J, Li D, Wang XB and Wu LJ:
Roles of PI3-K/Akt pathways in nanoparticle realgar powders-induced
apoptosis in U937 cells. Acta Pharmacol Sin. 29:355–363. 2008.
View Article : Google Scholar : PubMed/NCBI
|
